Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.
Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.21% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease. The Denmark-based biotechnology company said the drug is currently in a Phase 3 trial for uncontrolled hypertension and advanced chronic kidney disease.
“This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk. The deal is expected to close before the end of 2023. Novo Nordisk’s U.S.-listed shares, which fell 0.8% in premarket trading, have run up 27.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
‘Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdlesTwo experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly’s obesity drugs.
Weiterlesen »
'Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdlesTwo experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly's obesity drugs.
Weiterlesen »
How to avoid, identify and treat concussionsWhat can you do to protect, identify and treat a concussion? Scientist Julie Stamm, author of the book “The Brain on Youth Sports,” offers five tips to raise awareness.
Weiterlesen »
Treat yourself to a budget-friendly, S Pen-powered Galaxy Tab S6 Lite tablet at an irresistible price on ...The tablet has good performance and is worth every single penny spent
Weiterlesen »
Takeaways from Nuggets’ lone home preseason game of 2023: Nikola Jokic and Jamal Murray give Ball Arena a treatBennett Durando is the Colorado Avalanche beat writer for The Denver Post. Before taking on his first NHL beat, he covered SEC football and other sports for five years, first at his alma mater, Missouri, for the St. Louis Post-Dispatch and Columbia Missourian, then Auburn for the Montgomery Advertiser.
Weiterlesen »
20 Little Luxuries That People Don't Mind Spending Money OnSometimes you just have to treat yourself to a latte at Starbucks to make your day better.
Weiterlesen »